Dermatology

Favorable Equivalency Studies of Candidate Biosimilar AVT04 and Reference Ustekinumab

March 27th 2023

By Justina Petrullo

Posters presented by Alvotech at 2023 American Academy of Dermatology (AAD) annual meeting showcased proven bioequivalence and therapeutic equivalence candidate biosimilar AVT04 and reference ustekinumab (Stelara).

Samsung Bioepis’ Stelara Biosimilar Proves Successful in Phase 1 Study

March 20th 2023

By Skylar Jeremias

Article

At the American Academy of Dermatology annual meeting, Samsung Bioepis shared positive results from a phase 1 study comparing its ustekinumab biosimilars (SB17) with the reference product (Stelara).

Retrospective Study Supports Safety of Anti-TNF Biosimilars During Pregnancy

March 18th 2023

By Deana Ferreri, PhD

Article

More and more women are becoming pregnant while on anti–tumor necrosis factor (TNF) biosimilars used to treat inflammatory disorders. However, there is “little data” on the safety and effectiveness of biosimilars in pregnancy, according to authors of a recent retrospective study.

CVS Predicts Interchangeability Won’t Drive Adalimumab Biosimilar Adoption

March 15th 2023

By Skylar Jeremias

Article

In a report from CVS Health, interchangeability will not be a primary factor in driving the adoption of adalimumab biosimilars referencing Humira, contradicting predictions from other sources that believe the designation will impact prescribing habits.

Eye on Pharma: FDA, EMA Accept Biosimilar Applications; Biosimilar Trials Begin

March 9th 2023

By Skylar Jeremias

Article

The FDA and the European Medicines Agency (EMA) accepted applications for a trastuzumab biosimilar and an ustekinumab biosimilar, respectively, and Altos Biologics completed patient enrollment for a phase 3 trial assessing an aflibercept biosimilar.

Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab Biosimilars

February 23rd 2023

By Skylar Jeremias

Article

In Cardinal Health’s 2023 Biosimilars Report, more than 60% of surveyed providers said they would only want to prescribe adalimumab biosimilars with interchangeability designations, suggesting the label may have a greater impact on uptake than originally expected.

Study: Does Adalimumab Lose Effectiveness After Switching to a Biosimilar?

January 7th 2023

By Skylar Jeremias

Article

The authors of an retrospective real-world study of patients with hidradenitis suppurativa treated with adalimumab concluded that switching patients between adalimumab products risked a greater likelihood of loss of effectiveness.

Improved Biosimilar Uptake Saved Health System $26.9M Over 2 Years

March 28th 2022

By Laura Joszt

Article

A series of initiatives to improve uptake of the biosimilars for 7 originator biologics resulted in significant savings for Providence St. Joseph Health.

Hospitals, Physician Offices Significantly Mark Up Prices for 3 Drugs With Biosimilars

February 21st 2022

By Laura Joszt

Article

A report from AHIP found 3 drugs that have multiple biosimilars available can be delivered more affordably through specialty pharmacies.

Nova Scotia Becomes Fifth Canadian Province to Implement a Biosimilar Switching Program

February 5th 2022

By Skylar Jeremias

Article

The province is the latest jurisdiction to adopt a program that will require patients to switch away from expensive reference biologics to select biosimilars for certain conditions.